2.50
Hdl Handle:
http://hdl.handle.net/10547/578857
Title:
New targets for the immunotherapy of colon cancer—does reactive disease hold the answer?
Authors:
Boncheva, Viktoriya Bogdanova; Bonney, S.A.; Brooks, Suzanne E.; Tangney, Mark; O'Sullivan, Gerald C.; Mirnezami, A.; Guinn, Barbara-Ann
Abstract:
Colorectal cancer (CRC) is one of the most commonly diagnosed cancers in both men and women, posing a serious demographic and economic burden worldwide. In the United Kingdom, CRC affects 1 in every 20 people and it is often detected once well established and after it has spread beyond the bowel (Stage IIA-C and Stage IIIA-C). A diagnosis at such advanced stages is associated with poor treatment response and survival. However, studies have identified two sub-groups of post-treatment CRC patients--those with good outcome (reactive disease) and those with poor outcome (non-reactive disease). We aim to review the state-of-the-art for CRC with respect to the expression of cancer-testis antigens (CTAs) and their identification, evaluation and correlation with disease progression, treatment response and survival. We will also discuss the relationship between CTA expression and regulatory T-cell (Treg) activity to tumorigenesis and tumor immune evasion in CRC and how this could account for the clinical presentation of CRC. Understanding the molecular basis of reactive CRC may help us identify more potent novel immunotherapeutic targets to aid the effective treatment of this disease. In this review, based on our presentation at the 2012 International Society for the Cell and Gene Therapy of Cancer annual meeting, we will summarize some of the most current advances in CTA and CRC research and their influence on the development of novel immunotherapeutic approaches for this common and at times difficult to treat disease.
Citation:
Boncheva, V., Bonney, S.A.., Brooks, S.E., Tangney, M., O'Sullivan, G.C., Mirnezami, A., Guinn, B.A. (2013) 'New targets for the immunotherapy of colon cancer—does reactive disease hold the answer?' Cancer Gene Therapy 20 (3):157
Publisher:
Nature Publishing Group
Journal:
Cancer Gene Therapy
Issue Date:
15-Mar-2013
URI:
http://hdl.handle.net/10547/578857
DOI:
10.1038/cgt.2013.5
Additional Links:
http://www.nature.com/doifinder/10.1038/cgt.2013.5
Type:
Article
Language:
en
ISSN:
0929-1903; 1476-5500
Appears in Collections:
Biomedicine and Nutrition Research Group

Full metadata record

DC FieldValue Language
dc.contributor.authorBoncheva, Viktoriya Bogdanovaen
dc.contributor.authorBonney, S.A.en
dc.contributor.authorBrooks, Suzanne E.en
dc.contributor.authorTangney, Marken
dc.contributor.authorO'Sullivan, Gerald C.en
dc.contributor.authorMirnezami, A.en
dc.contributor.authorGuinn, Barbara-Annen
dc.date.accessioned2015-09-29T08:33:58Zen
dc.date.available2015-09-29T08:33:58Zen
dc.date.issued2013-03-15en
dc.identifier.citationBoncheva, V., Bonney, S.A.., Brooks, S.E., Tangney, M., O'Sullivan, G.C., Mirnezami, A., Guinn, B.A. (2013) 'New targets for the immunotherapy of colon cancer—does reactive disease hold the answer?' Cancer Gene Therapy 20 (3):157en
dc.identifier.issn0929-1903en
dc.identifier.issn1476-5500en
dc.identifier.doi10.1038/cgt.2013.5en
dc.identifier.urihttp://hdl.handle.net/10547/578857en
dc.description.abstractColorectal cancer (CRC) is one of the most commonly diagnosed cancers in both men and women, posing a serious demographic and economic burden worldwide. In the United Kingdom, CRC affects 1 in every 20 people and it is often detected once well established and after it has spread beyond the bowel (Stage IIA-C and Stage IIIA-C). A diagnosis at such advanced stages is associated with poor treatment response and survival. However, studies have identified two sub-groups of post-treatment CRC patients--those with good outcome (reactive disease) and those with poor outcome (non-reactive disease). We aim to review the state-of-the-art for CRC with respect to the expression of cancer-testis antigens (CTAs) and their identification, evaluation and correlation with disease progression, treatment response and survival. We will also discuss the relationship between CTA expression and regulatory T-cell (Treg) activity to tumorigenesis and tumor immune evasion in CRC and how this could account for the clinical presentation of CRC. Understanding the molecular basis of reactive CRC may help us identify more potent novel immunotherapeutic targets to aid the effective treatment of this disease. In this review, based on our presentation at the 2012 International Society for the Cell and Gene Therapy of Cancer annual meeting, we will summarize some of the most current advances in CTA and CRC research and their influence on the development of novel immunotherapeutic approaches for this common and at times difficult to treat disease.en
dc.language.isoenen
dc.publisherNature Publishing Groupen
dc.relation.urlhttp://www.nature.com/doifinder/10.1038/cgt.2013.5en
dc.rightsArchived with thanks to Cancer Gene Therapyen
dc.subjectcancer gene therapyen
dc.subjectimmunotherapyen
dc.subjectcolon canceren
dc.subjectreactive diseaseen
dc.titleNew targets for the immunotherapy of colon cancer—does reactive disease hold the answer?en
dc.typeArticleen
dc.identifier.journalCancer Gene Therapyen
All Items in UOBREP are protected by copyright, with all rights reserved, unless otherwise indicated.